SCHEDULE: BlackRock Discloses 5.2% Stake in Urogen Pharma
Beneficial Ownership Filing
BlackRock, Inc. has reported beneficial ownership of 5.2% of Urogen Pharma Ltd's common stock as of March 31, 2026.
Summary
- BlackRock, Inc. has filed a Schedule 13G, indicating it beneficially owns 2,519,771 shares of Urogen Pharma Ltd's common stock.
- This ownership stake represents 5.2% of the class of securities.
- The filing is made in accordance with Rule 13d-1(b) and BlackRock, Inc. is classified as a holding company (HC).
- The reporting date for this event is March 31, 2026.
- BlackRock's reporting business units have sole voting power over 2,461,477 shares and sole dispositive power over 2,519,771 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership by a large institutional investor and does not contain new operational or financial performance information.
Positives
- BlackRock, a significant institutional investor, has disclosed a substantial ownership stake, which can be viewed positively by the market.
- The filing indicates clear and sole dispositive and voting power for a significant portion of the shares held, suggesting conviction in the investment.
Risks
- While not explicitly stated as a risk in this filing, significant institutional ownership can sometimes lead to increased volatility if large blocks are traded.
- The filing does not provide forward-looking statements or specific strategic insights into Urogen Pharma, limiting the ability to assess future performance risks.
Future Outlook
This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Urogen Pharma's future performance.
Management Comments
- BlackRock, Inc. certifies that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.
Industry Context
StockSavvy.ai notes that Schedule 13G filings from major institutional investors like BlackRock are common and indicate significant investment positions. The 5.2% stake suggests BlackRock views Urogen Pharma as a notable investment within the pharmaceutical sector.
Stakeholder Impact
- Shareholders: The disclosure of a significant stake by BlackRock may be perceived positively, potentially influencing investor sentiment.
- Management of Urogen Pharma: The increased visibility from a major institutional holder like BlackRock could lead to greater scrutiny and engagement.
Next Steps
- BlackRock, Inc. will continue to hold or manage its investment in Urogen Pharma Ltd's common stock.
- Further filings may be required if BlackRock's ownership stake changes significantly.
Key Dates
| Date | Description |
|---|---|
| 04/30/2023 | Previous power of attorney dated for BlackRock, Inc. |
| 01/21/2025 | Date of execution for the current Power of Attorney for BlackRock, Inc. |
| 03/31/2026 | Date of event requiring the filing of this Schedule 13G. |
| 04/27/2026 | Date of certification and signature by Spencer Fleming, Managing Director for BlackRock, Inc. |
Keywords
Schedule 13G, BlackRock, Urogen Pharma, Institutional Ownership, Common Stock, Beneficial Ownership, SEC Filing, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.